EnzyTag
Private Company
Funding information not available
Overview
EnzyTag is a private, venture-backed biotech firm commercializing an enzymatic peptide ligation platform (Peptiligase) for drug discovery and manufacturing. Its Chemo-Enzymatic Peptide Synthesis (CEPS) and Expressed Protein Ligation (EPL) technologies offer significant advantages over traditional solid-phase synthesis, including higher yields, lower costs, greener processes, and the ability to create monodisperse conjugates. The company operates as a technology licensor, aiming to partner with pharmaceutical and biotech companies to develop and manufacture advanced peptide-based therapeutics and conjugates.
Technology Platform
Exclusive licensee of the patented Peptiligase technology for enzymatic peptide ligation. Platform includes Chemo-Enzymatic Peptide Synthesis (CEPS) for efficient peptide manufacturing and Expressed Protein Ligation (EPL) for creating monodisperse bioconjugates like ADCs, PROTACs, and LYTACs.
Opportunities
Risk Factors
Competitive Landscape
EnzyTag competes in the peptide synthesis and bioconjugation tool space against established solid-phase synthesis providers, other enzymatic platforms (e.g., sortase-based), and chemical conjugation methods. Its key differentiators are the exclusive Peptiligase license, the ability to produce monodisperse conjugates, and strong sustainability claims.